HAYWARD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated ( Nachrichten ) presented results from a Phase 1 clinical trial of its second-generation Hsp90 inhibitor, alvespimycin HCl (KOS-1022), showing encouraging signs of anti-leukemia activity in a highly refractory patient population and tolerable toxicity.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment